Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Dosage Regimen: Individualization01:24

Dosage Regimen: Individualization

279
Individualization in dosing regimens is the customization of medication doses for individual patients. Its necessity arises from the goal of maximizing therapeutic benefits while minimizing risks. This approach is pivotal because human responses to drugs can vary widely; what is effective for one person may be inadequate or excessive for another. Interpatient (intersubject) variability refers to differences in drug responses between individuals, while intrapatient (intrasubject) variability...
279
Dosage Regimens: Designs and Approaches01:28

Dosage Regimens: Designs and Approaches

456
Designing a dosage regimen, which refers to the manner of drug administration, is a complex process involving the selection of drug dose, route, and frequency. This process is underpinned by pharmacokinetic parameters derived from tests and population averages. These parameters are then tailored to patient-specific variables such as diagnosis, demographics, and allergy status. Once therapy commences, therapeutic response monitoring is critical and achieved through clinical and physical...
456
Dosage Regimens: Partial Pharmacokinetic Parameters01:01

Dosage Regimens: Partial Pharmacokinetic Parameters

254
It is not uncommon for complete drug pharmacokinetic profiles to remain elusive in pharmacokinetics. This necessitates certain educated assumptions by pharmacokineticists to determine appropriate dosage regimens without comprehensive pharmacokinetic data from animal or human studies. One prevalent assumption is setting the bioavailability factor, denoted as F, to 1 or 100%. This assumption caters to the scenario where a drug doesn't achieve full systemic absorption, resulting in the patient...
254
Dose Size and Dosing Frequency: Determination Methods01:21

Dose Size and Dosing Frequency: Determination Methods

498
Determining the optimal dose size and dosing frequency in pharmacotherapy is crucial for achieving therapeutic effectiveness while minimizing adverse effects. This article explores the methodologies employed in determining these parameters, focusing on their significance and interplay to tailor dosing regimens.Dose Size: Dose size refers to the amount of a drug administered in a single dose. It is determined based on the drug's pharmacodynamics and pharmacokinetics properties and...
498
Determination of Multiple Dosing Parameters: Loading and Maintenance Doses01:25

Determination of Multiple Dosing Parameters: Loading and Maintenance Doses

346
A loading dose is an essential pharmacological strategy to rapidly achieve the target plasma drug concentration necessary for an immediate therapeutic effect. This approach is especially critical for drugs characterized by slow absorption or extended half-lives, where delaying therapeutic plasma levels could compromise treatment outcomes. By administering a loading dose, clinicians ensure a prompt onset of drug action, even for agents with complex pharmacokinetic profiles.Achieving steady-state...
346
Drug Accumulation During Multiple Dosing: Repetitive IV Injections01:21

Drug Accumulation During Multiple Dosing: Repetitive IV Injections

378
Calculating drug dosage and accumulation in multiple-dose regimens is crucial for achieving therapeutic efficacy while avoiding toxicity. This involves determining the plasma drug concentrations over time to optimize dosing schedules. The principle of superposition is fundamental in this process, allowing for the prediction of drug concentration in plasma following multiple doses based on single-dose data.The principle of superposition asserts that the plasma concentration-time curves from...
378

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Incidence and risk factors of major bleeding following major orthopaedic surgery with fondaparinux thromboprophylaxis. A time-to-event analysis.

British journal of clinical pharmacology·2018
Same author

Warfarin Dosing Algorithms Underpredict Dose Requirements in Patients Requiring ≥7 mg Daily: A Systematic Review and Meta-analysis.

Clinical pharmacology and therapeutics·2017
Same author

A Philosophical Framework for Integrating Systems Pharmacology Models Into Pharmacometrics.

CPT: pharmacometrics & systems pharmacology·2016
Same author

Quantification of the Forgiveness of Drugs to Imperfect Adherence.

CPT: pharmacometrics & systems pharmacology·2015
Same author

A model-based meta-analysis of the influence of factors that impact adherence to medications.

Journal of clinical pharmacy and therapeutics·2014
Same author

Scale reduction of a systems coagulation model with an application to modeling pharmacokinetic-pharmacodynamic data.

CPT: pharmacometrics & systems pharmacology·2014

Related Experiment Video

Updated: Mar 24, 2026

Experimental Quantification of Interactions Between Drug Delivery Systems and Cells In Vitro: A Guide for Preclinical Nanomedicine Evaluation
08:47

Experimental Quantification of Interactions Between Drug Delivery Systems and Cells In Vitro: A Guide for Preclinical Nanomedicine Evaluation

Published on: September 28, 2022

2.4K

A framework for quantifying the influence of adherence and dose individualization.

P Assawasuwannakit1,2, R Braund1, S B Duffull1

  • 1School of Pharmacy, University of Otago, Dunedin, New Zealand.

Clinical Pharmacology and Therapeutics
|March 10, 2016
PubMed
Summary

Drug forgiveness quantifies therapeutic success likelihood with imperfect adherence. New concepts, a priori and a posteriori forgiveness, help differentiate adherence and dose individualization impacts for better patient outcomes.

More Related Videos

Validated LC-MS/MS Panel for Quantifying 11 Drug-Resistant TB Medications in Small Hair Samples
08:54

Validated LC-MS/MS Panel for Quantifying 11 Drug-Resistant TB Medications in Small Hair Samples

Published on: May 19, 2020

8.3K
Stepwise Dosing Protocol for Increased Throughput in Label-Free Impedance-Based GPCR Assays
06:13

Stepwise Dosing Protocol for Increased Throughput in Label-Free Impedance-Based GPCR Assays

Published on: February 21, 2020

7.1K

Related Experiment Videos

Last Updated: Mar 24, 2026

Experimental Quantification of Interactions Between Drug Delivery Systems and Cells In Vitro: A Guide for Preclinical Nanomedicine Evaluation
08:47

Experimental Quantification of Interactions Between Drug Delivery Systems and Cells In Vitro: A Guide for Preclinical Nanomedicine Evaluation

Published on: September 28, 2022

2.4K
Validated LC-MS/MS Panel for Quantifying 11 Drug-Resistant TB Medications in Small Hair Samples
08:54

Validated LC-MS/MS Panel for Quantifying 11 Drug-Resistant TB Medications in Small Hair Samples

Published on: May 19, 2020

8.3K
Stepwise Dosing Protocol for Increased Throughput in Label-Free Impedance-Based GPCR Assays
06:13

Stepwise Dosing Protocol for Increased Throughput in Label-Free Impedance-Based GPCR Assays

Published on: February 21, 2020

7.1K

Area of Science:

  • Pharmacology
  • Clinical Pharmacy
  • Drug Dosing

Background:

  • Patient adherence and individualized dosing are critical for therapeutic success.
  • Non-adherence and failure to personalize drug doses can lead to poor patient outcomes.
  • The concept of drug 'forgiveness' addresses the impact of imperfect adherence on treatment efficacy.

Purpose of the Study:

  • To introduce and define two novel concepts: a priori forgiveness and a posteriori forgiveness.
  • To quantitatively distinguish the influence of patient adherence from dose individualization.
  • To provide a framework for developing clinical guidelines on adherence and dose individualization.

Main Methods:

  • Conceptual framework development for drug forgiveness.
  • Introduction of a priori forgiveness (without dose individualization) and a posteriori forgiveness (with dose individualization).
  • Illustrative case examples demonstrating the application of these concepts.

Main Results:

  • A quantitative measure is proposed to assess drug forgiveness.
  • The framework allows for the disentanglement of adherence and dose individualization effects.
  • Identified scenarios where adherence is paramount versus where dose individualization is critical.

Conclusions:

  • A priori and a posteriori forgiveness offer a quantitative approach to evaluate drug efficacy.
  • These concepts can guide clinical practice by clarifying the relative importance of adherence and dose individualization.
  • The framework supports optimizing patient outcomes by addressing both adherence and personalized dosing strategies.